Heparin |
Catalog No.GC10829 |
injectable anticoagulant
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 9005-49-6
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Heparin, a highly sulfated glycosaminoglycan, has been widely used as an injectable anticoagulant. Heparin is present only in a few tissues and species of the animal kingdom and in the form of granules inside organelles in the cytoplasm of special cells. Heparin might be involved in defense mechanisms against bacteria and other foreign materials [1].
In vitro: Heparin (25-500 Nμ/ml) dose-dependently inhibited cellular aggregation and degranulation induced either by FMLP or by zymosan-activated serum. Heparin at the concentration of25 μg/ml specifically inhibited FMLP-dependent superoxide anion generation and chemiluminescence. Heparin inhibited all the aspects of the functional and metabolic granulocyte activation [2].
In vivo: In the cells from heparin-treated rats or in the heparin-treated cells, specific binding of [125I]iodo-angiotensin II was decreased due to a decrease in both the number and the affinity of angiotensin II receptors. Heparin also decreased the maximum angiotensin Il-induced productionof aldosterone in the cells from heparin-treated rats and in the heparin-treated cells. Heparin interacted with adrenal angiotensin II receptors to inhibit the angiotensin Il-induced aldosterone production [3].
References:
[1]. Nader H B, Chavante S F, Dos-Santos E A, et al. Heparan sulfates and heparins: similar compounds performing the same functions in vertebrates and invertebrates[J]. Brazilian Journal of Medical and Biological Research, 1999, 32(5): 529-538.
[2]. Pasini F L, Pasqui A L, Ceccatelli L, et al. Heparin inhibition of polymorphonuclear leukocyte activation in vitro. A possible pharmacological approach to granulocyte-mediated vascular damage[J]. Thrombosis research, 1984, 35(5): 527-537.
[3]. Azukizawa S, Iwasaki I, Kigoshi T, et al. Effects of heparin treatments in vivo and in vitro on adrenal angiotensin II receptors and angiotensin II-induced aldosterone production in rats[J]. Actaendocrinologica, 1988, 119(3): 367-372.
Cas No. | 9005-49-6 | SDF | |
Canonical SMILES | CC(NC1C(O)C(OC2C(OS(=O)(O)=O)C(O)C(OC3C(NS(=O)(O)=O)C(OS(=O)(O)=O)C(OC4C(OS(=O)(O)=O)C(O)C(O)C(C(O)=O)O4)C(CO)O3)C(C(O)=O)O2)C(COS(=O)(O)=O)OC1O)=O | ||
Formula | C26H42N2O37S5 | M.Wt | 1134.93 |
Solubility | ≥ 12.75mg/ml in Water | Storage | Store at -20°C, sealed storage, protect from light |
General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. |
Prepare stock solution | |||
1 mg | 5 mg | 10 mg | |
1 mM | 0.8811 mL | 4.4056 mL | 8.8111 mL |
5 mM | 0.1762 mL | 0.8811 mL | 1.7622 mL |
10 mM | 0.0881 mL | 0.4406 mL | 0.8811 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Average Rating: 5
(Based on Reviews and 10 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *